Globe Newswire (Thu, 19-Feb 9:00 AM ET)
Globe Newswire (Tue, 17-Feb 8:05 AM ET)
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Globe Newswire (Wed, 11-Feb 8:45 AM ET)
Globe Newswire (Tue, 6-Jan 8:35 AM ET)
Globe Newswire (Wed, 31-Dec 4:15 PM ET)
Outlook Therapeutics Announces New Employment Inducement Grants
Globe Newswire (Fri, 26-Dec 5:00 PM ET)
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Globe Newswire (Fri, 19-Dec 8:05 AM ET)
Market Chameleon (Thu, 13-Nov 5:36 AM ET)
Market Chameleon (Mon, 29-Sep 7:59 AM ET)
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics trades on the NASDAQ stock market under the symbol OTLK.
As of March 2, 2026, OTLK stock price climbed to $0.43 with 109,105 million shares trading.
OTLK has a beta of 1.47, meaning it tends to be more sensitive to market movements. OTLK has a correlation of 0.02 to the broad based SPY ETF.
OTLK has a market cap of $31.61 million. This is considered a Sub-Micro Cap stock.
Last quarter Outlook Therapeutics reported $-1 million in Revenue and -$.22 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.05.
In the last 3 years, OTLK traded as high as $40.60 and as low as $.38.
The top ETF exchange traded funds that OTLK belongs to (by Net Assets): VTI, VXF, IWC.
OTLK has underperformed the market in the last year with a price return of -68.8% while the SPY ETF gained +18.1%. OTLK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.4% and -12.2%, respectively, while the SPY returned +0.9% and +0.3%, respectively.
OTLK support price is $.40 and resistance is $.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OTLK shares will trade within this expected range on the day.
